This policy briefing summarizes trends in reported experiences (from primary and secondary research) in the use of regulatory agilities in clinical trials observed since the start of the pandemic, reported challenges to their implementation and forward looking recommendations, whether to prepare for the next pandemic or to modernize standard normative processes to accelerate patient access to safe and effective medicines.
Read more
This policy briefing summarizes trends in reported experiences (from primary and secondary research) in the use of these agilities observed since the start of the pandemic, some reported challenges to their implementation and forward-looking recommendations, whether to prepare for the next pandemic or to strengthen standard normative processes to accelerate patient access to safe and effective medicines and vaccines.
Read more
The Biopharmaceutical CEO Roundtable (BCR) delegation exchanged views on how the German government and industry can work together to reinvigorate innovation across the life sciences eco-system.
Read moreOur efforts against COVID-19 have surfaced critical learnings, including the need to establish a global foundational capability, fit for purpose ahead of the next health emergency.
Read moreOver the last two years, the global healthcare community’s efforts in mounting a response to COVID-19 have materialised. This pandemic has brought home the power of vaccines to save lives and protect the vulnerable.
Read moreIFPMA, the body representing biopharmaceutical companies in Geneva, expresses deep disappointment with the decision taken to adopt a TRIPS waiver, despite intellectual property (IP) not being a barrier to vaccine scale-up and wide acknowledgment of vaccines surplus.
Read moreThe biopharmaceutical industry has been at the forefront of the response to the current pandemic and, as a result, is uniquely positioned to contribute to future pandemic preparedness discussions. We welcome the opportunity to comment on this white paper and stand ready to contribute with the private sector’s expertise as the INB’s work progresses. Given...
Read moreRead our perspective, which includes examples and case studies of how members contribute their expertise and knowledge to expand the clinical research infrastructure in LMICs.
Read more
The associations representing the global research-based biopharmaceutical industry reaffirm that weakening the intellectual property (IP) framework as proposed in the “Quad compromise” is unnecessary and harmful to innovation. An IP waiver does not address inequitable access to COVID-19 vaccines and will put global health security at risk. It will undermine innovation and industry’s ability to...
Read moreThe WHO Global Influenza Surveillance and Response System (GISRS) celebrates this year its 70th anniversary, marking decades of successful information sharing and collaboration for influenza surveillance, preparedness and response. Its expansion to GISRS+ to include other respiratory pathogens must ensure that influenza surveillance is not deprioritized nor negatively impacted. With regards the EB150 request for...
Read moreCOVID-19 has reminded us that those with chronic conditions and co-morbidities are often the most vulnerable and have suffered the most throughout the pandemic.
Read moreWhile the world is still grappling with COVID-19, the global community needs to look ahead to how it can learn from this experience and better prepare for the next health crisis. Ending this pandemic and preparing for the next one demands an end-to-end, lab-to-last-mile strategy. The world needs to act globally and locally to improve...
Read more